RSS | Login | Register

Alzheimer's Dementia Drug Treatments

September 24, 2009

Print
Email
Reprint
Permissions
Font Size: A | A | A

Alzheimer's Dementia (download)

DRUGS FOR ALZHEIMER'S DEMENTIA

Generic	Brand	Formulation/Strengths (mg)	Usual Regimen*
CHOLINESTERASE INHIBITORS
Donepezil	Aricept	Tabs: 5mg, 10mg ODT: 5mg, 10mg	Mild-moderate: 5mg daily at bedtime Severe: 5mg daily for 4–6 weeks then 10mg daily at bedtime
Galantamine	Razadyne	Tabs: 4mg, 8mg, 12mg Soln: 4mg/mL	Initial: 4mg twice daily Maintenance: Initially 4mg twice daily; if well-tolerated may increase by 4mg twice daily at intervals of ≥4 weeks; max 12mg twice daily (24mg/day)
Galantamine ER	Razadyne ER	Caps: 8mg, 16mg, 24mg	Initial: 8mg once daily in AM Maintenance: if well-tolerated may increase by 8mg/day at intervals of ≥4 weeks; max 24mg/day
Rivastigmine	Exelon	Caps: 1.5mg, 3mg, 4.5mg, 6mg Soln: 2mg/mL Patches: 4.6mg/24hours, 9.5mg/24hours	Caps or soln: initially 1.5mg twice daily; may increase by 1.5mg twice daily at intervals of at least 2 weeks Patch: initially apply one 4.6mg/24hrs patch once daily; if tolerated may increase to 9.5mg/24hrs patch after 4 weeks
Tacrine	Cognex	Caps: 10mg, 20mg, 30mg, 40mg	Initial: 10mg 4 times daily Maintenance: If no transaminase elevations and tolerated, increase by 40mg/day in divided doses at ≥4 week intervals to max 160mg/day
N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST
Memantine	Namenda	Tabs: 5mg, 10mg Soln: 2mg/mL	Initial: 5mg once daily. Maintenance: titrate at intervals of at least 1 week to 5mg twice daily, then to 5mg and 10mg as separate doses, then to 10mg twice daily
NOTES
Caps = capsules; Tabs = tablets; ODT = orally-disintegrating tablets; Soln = solution *For additional dosing information, including renal and hepatic impairment, titration and maximum recommended dose, see product labeling. (Rev. 9/2007)

| Share

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

FDA accepts NDA for extended release Aricept, a treatment for Alzheimer's disease (AD)

November 25, 2009

Eisai and Pfizer announced that the FDA has accepted for review the New Drug Application (NDA) for once-daily 23 mg Aricept (donepezil HCl extended release tablets) for the treatment of moderate to severe Alzheimer's disease (AD).

Phase 3 study of Dimebon and donepezil combination therapy for Alzheimer's disease

April 15, 2009

Pfizer and Medivation, Inc announced the initiation of a 12-month, Phase 3 trial of the investigational drug Dimebon in combination with donepezil HCl for the treatment of mild-to-moderate Alzheimer's disease (AD).

Phase 1 study of MCD-386 for Alzheimer's disease

April 08, 2009

Mithridion, Inc. announced results from a Phase 1 study of MCD-386, its lead drug candidate for Alzheimer's disease (AD).

Axona available for Alzheimer's disease

March 03, 2009

Axona (caprylidene, from Accera) has been launched as a medical food for the dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease (AD).